Corticosteroid-Only Arm Worth Public Health Risk In Antifungal Trials - Cmte.
Executive Summary
The benefits of studying a stand-alone corticosteroid arm in a trial comparing an antifungal/corticosteroid combination to an antifungal outweigh public health concerns raised by patient exposure to the corticosteroid, FDA's Dermatologics & Ophthalmics Committee concluded.